Weekly Paclitaxel as Third-line Chemotherapy in Patients With Metastatic Transitional Cell Carcinoma of Urothelial Tract: Results of a Phase II Study

被引：0
|
作者：
Rozzi, A. [1 ]
Nardoni, C. [1 ]
Corona, M. [1 ]
Falbo, T. [2 ]
De Marco, F. [3 ]
Grillenzoni, L. [3 ]
Lanzetta, G. [4 ]
机构：
[1] Ist Neurotraumatol, Clin Oncol Unit, I-00185 Grottaferrata, Italy
[2] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy
[3] Ist Neurotraumatol Italiano INI Grottaferrata, Div Urol, Rome, Italy
[4] Ist Neurotraumatol Italiano INI Grottaferrata, Clin Oncol Unit, Rome, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72059-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S518 / S518
页数：1
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
    Rozzi, Antonio
    Santini, Daniele
    Salerno, Margherita
    Bordin, Francesca
    Mancuso, Andrea
    Minniti, Giuseppe
    Nardoni, Chiara
    Corona, Michela
    Falbo, Pina Tiziana
    Recine, Federica
    Lanzetta, Gaetano
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [2] Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
    Antonio Rozzi
    Daniele Santini
    Margherita Salerno
    Francesca Bordin
    Andrea Mancuso
    Giuseppe Minniti
    Chiara Nardoni
    Michela Corona
    Pina Tiziana Falbo
    Federica Recine
    Gaetano Lanzetta
    Medical Oncology, 2013, 30
  • [3] Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
    Rozzi, Antonio
    Salerno, Margherita
    Bordin, Francesca
    De Marco, Ferdinando
    Di Nicola, Stefano
    Lanzetta, Gaetano
    MEDICAL ONCOLOGY, 2011, 28 : S426 - S432
  • [4] Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
    Antonio Rozzi
    Margherita Salerno
    Francesca Bordin
    Ferdinando De Marco
    Stefano Di Nicola
    Gaetano Lanzetta
    Medical Oncology, 2011, 28 : 426 - 432
  • [5] Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
    Berruti, Alfredo
    Sperone, Paola
    Ferrero, Anna
    Germano, Antonina
    Ardito, Arianna
    Priola, Adriano Massimiliano
    De Francia, Silvia
    Volante, Marco
    Daffara, Fulvia
    Generali, Daniele
    Leboulleux, Sophie
    Perotti, Paola
    Baudin, Eric
    Papotti, Mauro
    Terzolo, Massimo
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (03) : 451 - 458
  • [6] A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma
    Kim, Young Saing
    Lee, Soon Il
    Park, Se Hoon
    Park, Silvia
    Hwang, In Gyu
    Lee, Sang-Cheol
    Sun, Jong-Mu
    Lee, Jeeyun
    Lim, Ho Yeong
    CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : 76 - 81
  • [7] PHASE II STUDY OF OXALIPLATIN AS THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Sikder, S. K.
    Rahman, M.
    Saha, R. K.
    ANNALS OF ONCOLOGY, 2010, 21 : 219 - 219
  • [8] Third-Line Chemotherapy for Metastatic Urothelial Cancer A Retrospective Observational Study
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Bellelli, Teresa
    Romano, Concetta
    Montanaro, Vittorino
    Ferro, Matteo
    Benincasa, Alfonso
    Ribera, Dario
    Lucarelli, Giuseppe
    De Cobelli, Ottavio
    Sonpavde, Guru
    De Placido, Sabino
    MEDICINE, 2015, 94 (51)
  • [9] GEMCITABINE PLUS PACLITAXEL AS THIRD LINE CHEMOTHERAPY: A FEASIBLE OPTION FOR METASTATIC UROTHELIAL CARCINOMA PATIENTS
    Naiki, Taku
    Iida, Keitaro
    Ando, Ryosuke
    Etani, Toshiki
    Kawai, Noriyasu
    Nagai, Takashi
    Sugiyama, Yosuke
    Kondo, Masahiro
    Okamura, Takehiko
    Yasui, Takahiro
    JOURNAL OF UROLOGY, 2016, 195 (04): : E74 - E74
  • [10] Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
    Bajorin, DF
    McCaffrey, JA
    Hilton, S
    Mazumdar, M
    Kelly, WK
    Scher, HI
    Spicer, J
    Herr, H
    Higgins, G
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2722 - 2727
12345